| Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies IJ Findlay, GN De Iuliis, RJ Duchatel, ER Jackson, NA Vitanza, JE Cain, ... Oncogene 41 (4), 461-475, 2022 | 60 | 2022 |
| Signal transduction in diffuse intrinsic pontine glioma RJ Duchatel, ER Jackson, F Alvaro, B Nixon, H Hondermarck, MD Dun Proteomics 19 (21-22), 1800479, 2019 | 52 | 2019 |
| Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma RJ Duchatel, A Mannan, AS Woldu, T Hawtrey, PA Hindley, AM Douglas, ... Neuro-oncology advances 3 (1), vdab169, 2021 | 39 | 2021 |
| ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma ER Jackson, RJ Duchatel, DE Staudt, ML Persson, A Mannan, S Yadavilli, ... Cancer research 83 (14), 2421-2437, 2023 | 33 | 2023 |
| B-cell lymphoma 6 (BCL6): from master regulator of humoral immunity to oncogenic driver in pediatric cancers T McLachlan, WC Matthews, ER Jackson, DE Staudt, AM Douglas, ... Molecular Cancer Research 20 (12), 1711-1723, 2022 | 16 | 2022 |
| A review of the anti-tumor potential of current therapeutics targeting the mitochondrial protease ClpP in H3K27-altered, diffuse midline glioma ER Jackson, ML Persson, CJ Fish, IJ Findlay, S Mueller, J Nazarian, ... Neuro-oncology, Epub ahead of print, 2023 | 12 | 2023 |
| Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies ZP Germon, JR Sillar, A Mannan, RJ Duchatel, D Staudt, HC Murray, ... Science Signaling 16 (778), eabp9586, 2023 | 10 | 2023 |
| Dipg-03. Targeting pi3k using the blood brain barrier penetrable inhibitor, gdc-0084, for the treatment of diffuse intrinsic pontine glioma (dipg) R Duchatel, E Jackson, A Patabendige, J Cain, M Tsoli, M Monje, F Alvaro, ... Neuro-oncology 21 (Supplement_2), ii68-ii68, 2019 | 6 | 2019 |
| Correction to: Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection DE Staudt, HC Murray, DA Skerrett-Byrne, ND Smith, MFB Jamaluddin, ... Clinical Proteomics 20 (1), 16, 2023 | 4* | 2023 |
| PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma RJ Duchatel, ER Jackson, SG Parackal, D Kiltschewskij, IJ Findlay, ... The Journal of clinical investigation 134 (6), 2024 | 3 | 2024 |
| DIPG-29. Phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K) inhibition drives protein kinase c activation (PKC) in diffuse intrinsic pontine glioma (DIPG) RJ Duchatel, A Mannan, ER Jackson, D Staudt, DA Skerrett-Byrne, ... Neuro-oncology 22 (Supplement_3), iii292-iii293, 2020 | 3 | 2020 |
| Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma A Noll, C Myers, MC Biery, M Meechan, S Tahiri, A Rajendran, ME Berens, ... Neoplasia 43, 100921, 2023 | 1 | 2023 |
| Current status and advances to improving drug delivery in diffuse intrinsic pontine glioma LM Arms, RJ Duchatel, ER Jackson, PG Sobrinho, MD Dun, S Hua Journal of Controlled Release 370, 835-865, 2024 | | 2024 |
